AstraZeneca ($AZN) - Big Pharma's Q3 2010 Earnings Report

FiercePharma says: As Seroquel lawsuits pile up, AstraZeneca's profits have fallen 27 percent to $1.55 billion. The company has set aside $473 million for Seroquel payments and another $212 million for restructuring. It did pick up a 20 percent increase in Crestor sales, to $1.37 billion. Seroquel and Nexium will both face patent expirations in the next four years, putting pressure on Crestor and the rest of the company's pipeline to perform.

Highlights

  • Business EPS was up 8.6% in Q3 2010 on a reported basis and down 2.3% at CER
  • Core operating profit in the third quarter was down 10 percent at CER to $3.231 million
  • Core EPS in the third quarter was down 10 percent at CER to $1.50
  • Reported EPS in the third quarter was down 26 percent at CER to $1.08
  • Net cash distributions to shareholders for the nine months increased to $4.658 million through dividend payments of $3.361 million and net share repurchases of $1.297 million
  • Core EPS target for the full year narrowed to the range of $6.50 to $6.65

See AstraZeneca's current stock quote from CNN Money

AstraZeneca's website: http://www.astrazeneca.com/
Full earnings release: AstraZeneca earnings release

AstraZeneca ($AZN) - Big Pharma's Q3 2010 Earnings Report
Read more on

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.